24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
The purpose of this study is to evaluate the effect on 24-hour IOP reduction of netarsudil-latanoprost fixed combination in one eye compared to latanoprost alone in the contralateral eye, dosed daily, 1 drop at night (QD, PM) in adult subjects, at least 18 years of age, with open angle glaucoma (OAG) or ocular hypertension (OHT).
Eligibility criteria
Qualifiers
Diagnosis of OHT or mild-to-moderate OAG in both eyes (OAG in one eye and OHT in the fellow eye is acceptable) based on VF, OCT and dilated fundus examination within one year of the screening visit.
Both eyes must qualify for the study with an IOP of ≥18 mmHg but ≤34 mmHg on history or at the screening visit
Be able and willing to provide signed informed consent and follow study instructions
Ability to cooperate with the examinations required for the study and be able to attend all study visits
Disqualifiers
Subjects with narrow angles (3 quadrants with Grade 2 or less according to Shaffer Scale), angle closure or a history of angle closure, or peripheral iridotomy in either eye
Severe glaucomatous damage
Difference in IOP between eyes > 4 mmHg (unmedicated) at any baseline time point
Use of more than two ocular hypotensive medications within 30 days of screening
Trial design
Treatments tested in this trial
- Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution
- Latanoprost 0.005% Ophthalmic Solution
Treatment groups
30 Participants
are divided into 2 treatment groupsSponsors and collaborators
Mayo Clinic
Lead sponsor
Alcon Research
Collaborator
Source ClinicalTrials.gov